Blindsight

Blindsight is Neuralink's experimental sight device, a tiny grid of electrodes placed directly into the brain's visual cortex, which is the part of the brain that processes what we see. Instead of trying to repair a damaged eye, it writes visual information straight into the brain, and that creates small points of light called phosphenes. Because it skips the eye and the optic nerve completely, Neuralink says it could help people who have lost both eyes and their optic nerve, and even people who have been blind from birth, as long as the visual cortex is still intact. In September 2024, the United States Food and Drug Administration (FDA) granted Blindsight a Breakthrough Device Designation, a status that speeds up the development and review path for technologies that meet a serious unmet need.

What is Blindsight?

Blindsight creates the experience of sight in the brain rather than in the eye. The hardware underneath is Neuralink's N1 implant, the same device behind its first product, Telepathy, which lets paralyzed people control computers and phones with thought alone. Blindsight puts that same implant to a different use, sending organized patterns of light into the visual cortex so a blind person can start to make out shapes and motion.

Why Blindsight Exists

Every sight treatment you can buy today leans on some surviving piece of the eye, whether it is a retina to stimulate or a nerve to carry the signal. For a large group of people, including those who have lost both eyes, that piece is simply gone, and today's medicine has nothing to offer them. Blindsight is Neuralink's way to reach those people by going around the broken parts and speaking to the brain directly. It stretches the company's brain implant past paralysis and into restoring the senses, and it does that by starting from the basic science, which Elon calls first principles, instead of copying the eye-based approach that cannot solve this problem.

How it Works

The N1 is a coin-sized device that carries 1,024 electrodes on 64 ultra-thin, flexible polymer threads, and a surgical robot called R1 stitches those threads into the cortex. Careful pulses of electricity across those electrodes create phosphenes, and the arrangement of those dots forms a rough image, much like the dots on a stadium scoreboard form a picture. More electrodes mean more dots, and more dots mean a sharper picture, which is why Neuralink announced in January 2026 a plan to roughly triple the electrode count.

Elon has been clear that the first images will be rough and low resolution at first, with real room to get better over time. The N1 is the hardware, and Blindsight is the job it is asked to do.

The Economics of Blindsight

The vision program sits at the center of Neuralink's growth story. Its 650 million dollar Series E funding round, which closed in June 2025, pointed directly to the Blindsight and speech Breakthrough Device Designations as major steps forward. That round more than doubled the one before it, part of a steady climb in funding as the programs matured.

The Breakthrough Device Designation speeds up FDA review, which shortens the time to market for a device that serves a group of people with no eye-free rival. The opportunity is simple: a large group that no one else can reach, an ongoing relationship with each patient who gets an implant, and a cost per dot of light that should fall as electrode counts climb and surgeries become routine.

Current Status of Blindsight

As of late January 2026, no one had received a Blindsight implant yet, and trials are expected to begin during 2026 once regulators sign off. The clearest sign of momentum is the shared N1 hardware, where Neuralink's Telepathy program has grown from a single recipient in January 2024 to twenty-one participants enrolled worldwide two years later.

Each implant proves out the surgery and the recording setup that Blindsight leans on, and a sign-up list for vision candidates is already open and gathering demand ahead of the first surgery. Neuralink tells this story through people. First recipient Noland Arbaugh got back control of a computer and returned to college, and Brad, a participant with amyotrophic lateral sclerosis (ALS, a disease that destroys the nerves that control muscle), got back the ability to look around a room using a swivel camera he steers with his thoughts. Blindsight aims to add sight to that growing list of restored independence.

What Comes Next

The near-term plan is the jump in electrodes, the first Blindsight surgeries in people, and the factory capacity to support both. Elon has also raised the idea of sight beyond what humans normally have, including seeing in infrared or ultraviolet light, though that remains a goal rather than something shown to work.

The Bottom Line

Blindsight turns blindness from a problem of the eye into a problem of the brain, and by doing that it puts a group of patients with no options today on a clear, if unproven, path toward a first glimpse of light. Whether the dots ever sharpen into real sight is still an open question, but Neuralink is now building the trials, the electrodes, and the funding to find out. If anyone can pull it off, it is the greatest engineer of our time.

Related

Keep reading: N1 Implant, PRIME Study. Zoom out to the Neuralink overview, or open the Glossary.